Home/Pipeline/Mesalazine (Lifecycle Management)

Mesalazine (Lifecycle Management)

Ulcerative Colitis

Approved/Phase 3Active

Key Facts

Indication

Ulcerative Colitis

Phase

Approved/Phase 3

Status

Active

Company

Dr. Falk Pharma

About Dr. Falk Pharma

Dr. Falk Pharma is a well-established, research-based private company with over 60 years of expertise in gastroenterology and hepatology. It has successfully transitioned from a development-stage entity to a commercial organization, marketing a portfolio of approved small-molecule therapies for chronic conditions like ulcerative colitis, Crohn's disease, and primary biliary cholangitis. The company leverages its deep therapeutic area knowledge and the scientific platform of the affiliated Falk Foundation to drive innovation and maintain a strong market position in specialized gastrointestinal medicine. Its long-term, family-owned structure supports a focused and patient-centric strategy.

View full company profile

Therapeutic Areas

Gastroenterology Hepatology Metabolic Medicine

Other Ulcerative Colitis Drugs

Drug	Company	Phase	Status
BB265	BiomeBank	Phase 1	Active
PALI-2108	Palisade Bio	Phase 2	Advancing towards initiation
ALTB-268	AltruBio	Phase IIa	Active
AIM-HI-UC	PathAI	Clinical Trials	Active
Patient Stratification in Ulcerative Colitis	Enable Medicine	Research	Active
AhR Agonist Program	Azora Therapeutics	Phase 1b	Active
R-3750	Virtici	Phase 1	Active
GPR35 Inhibitor	ThirtyFiveBio	Preclinical	Active
BT-600	Biora Therapeutics	Phase 1	Active
Asacol® (mesalazine)	Tillotts Pharma	Approved	Active
MB310	Microbiotica	Phase 1b	Active
'1805	Revolo Biotherapeutics	Phase 2 (Planned)	Active